Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BiltRx vs Omada Health

BiltRx
Graded #57

Higher grade

vs+19.699999999999996
Omada Health
Graded #435

Lower grade

The verdict

BiltRx takes it — 75.3/100 to 55.6/100.

BiltRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. BiltRx is a US health-optimization telehealth platform spanning men's health, women's health, aesthetics and weight loss that offers compounded and brand-name GLP-1 medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBiltRx +46
91
45
Dose & formulationBiltRx +45
85
40
Clinical oversightOmada Health +3
74
77
Labs & monitoringOmada Health +9
52
61
FulfillmentBiltRx +9
71
62
Contract termsEven
55
55
BiltRx · left barOmada Health · right bar

The numbers

MetricBiltRxOmada Health
WeighScore75.3/10055.6/100
GradeCC
Scorecard rank#57#435
Semaglutide$125/mo (all doses, compounded)Not disclosed
Tirzepatide$129/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
BiltRx

Graded #57 · C

Strengths

  • Very low starting prices (semaglutide from 125 dollars, tirzepatide from 129 dollars)
  • LegitScript verified and HIPAA compliant
  • Names its 503A compounding pharmacies (Boothwyn and Southend)
  • Offers both compounded and brand-name GLP-1 options

Where it loses points

  • Covered states are behind a check-availability gate, not listed
  • Starting prices may rise depending on plan and dose
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard